Literature DB >> 1705319

Introduction of an activated RAS oncogene into murine bone marrow lymphoid progenitors via retroviral gene transfer results in thymic lymphomas.

C E Dunbar1, P S Crosier, A W Nienhuis.   

Abstract

Activating mutations within the various RAS protooncogenes have been detected in many human and murine hematopoietic neoplasms. Their causal significance has been difficult to assess, partly due to the lack of an animal model directly linking these mutations to hematopoietic neoplasms. A high-titer, helper-free recombinant retrovirus was used to introduce an activated Harvey RAS gene under the transcriptional control of the Moloney leukemia virus LTR into murine bone marrow cells. Eleven of fifteen mice reconstituted with these bone marrow cells developed fatal thymic lymphomas 10-12 week post-transplant. Analysis of DNA and RNA from tumor cells revealed the integrated proviral genome and provirally encoded RAS mRNA respectively. Immunophenotyping and T-cell receptor rearrangement analysis of fresh tumor cells and of cell lines derived from these tumors showed them to be T-cells arrested midway through thymic development. Despite evidence of proviral integration in marrow cells of mice with thymic tumors, no other hematologic abnormalities were detected. The short latency and reproducibility of thymic lymphoma development in mice transplanted with marrow transduced with this retrovirus suggests a direct causal effect of expression of an activated RAS gene in the transformation of a bone-marrow-derived lymphoid progenitor.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1705319

Source DB:  PubMed          Journal:  Oncogene Res        ISSN: 0890-6467


  7 in total

Review 1.  Regulation of monocyte differentiation by specific signaling modules and associated transcription factor networks.

Authors:  René Huber; Daniel Pietsch; Johannes Günther; Bastian Welz; Nico Vogt; Korbinian Brand
Journal:  Cell Mol Life Sci       Date:  2013-03-24       Impact factor: 9.261

2.  An internal deletion enhances the transcriptional activity of a recombinant retrovirus in hematopoietic cells in vivo.

Authors:  K L MacKenzie; L Bonham; G Symonds
Journal:  J Virol       Date:  1994-11       Impact factor: 5.103

Review 3.  Targeting oncogenic Ras signaling in hematologic malignancies.

Authors:  Ashley F Ward; Benjamin S Braun; Kevin M Shannon
Journal:  Blood       Date:  2012-08-16       Impact factor: 22.113

4.  K-RasG12D-induced T-cell lymphoblastic lymphoma/leukemias harbor Notch1 mutations and are sensitive to gamma-secretase inhibitors.

Authors:  Thomas Kindler; Melanie G Cornejo; Claudia Scholl; Jianing Liu; Dena S Leeman; J Erika Haydu; Stefan Fröhling; Benjamin H Lee; D Gary Gilliland
Journal:  Blood       Date:  2008-07-28       Impact factor: 22.113

5.  Conditional expression of oncogenic K-ras from its endogenous promoter induces a myeloproliferative disease.

Authors:  Iris T Chan; Jeffery L Kutok; Ifor R Williams; Sarah Cohen; Lauren Kelly; Hirokazu Shigematsu; Leisa Johnson; Koichi Akashi; David A Tuveson; Tyler Jacks; D Gary Gilliland
Journal:  J Clin Invest       Date:  2004-02       Impact factor: 14.808

6.  Somatic activation of oncogenic Kras in hematopoietic cells initiates a rapidly fatal myeloproliferative disorder.

Authors:  Benjamin S Braun; David A Tuveson; Namie Kong; Doan T Le; Scott C Kogan; Jacob Rozmus; Michelle M Le Beau; Tyler E Jacks; Kevin M Shannon
Journal:  Proc Natl Acad Sci U S A       Date:  2003-12-29       Impact factor: 11.205

7.  Transplantable myeloproliferative disease induced in mice by an interleukin 6 retrovirus.

Authors:  R G Hawley; A Z Fong; B F Burns; T S Hawley
Journal:  J Exp Med       Date:  1992-10-01       Impact factor: 14.307

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.